Researchers identify 'Achilles' heel' of PTEN that helps drive prostate cancer progression

February 13, 2017, Cold Spring Harbor Laboratory
Postdoctoral researchers Muhan Chen, Dawid G. Nowak and others in the Trotman lab at CSHL may have solved a mystery about prostate cancer: why some patients appear to have low levels of the powerful tumor-suppressing protein PTEN and yet have no mutations in the gene that encodes the protein. The answer is implied in this image. In a sample of mouse prostate tissue on the way to becoming cancerous, they show one area in which PTEN protein levels are high (Area 1, yellow dashes) and a nearby area (Area 2, red dashes) where they are low. Where PTEN is low, so are levels of a protein called Importin 11 (Ipo11); where PTEN is abundant, so too is Ipo11. Ipo11 saves PTEN proteins marked for destruction by carrying them into the cell nucleus, perhaps in this way forming a "reservoir" and saving PTEN for future use in the battle against the emerging tumor. When Ipo11 is missing, cancer progression is promoted. Credit: Trotman Lab, CSHL

Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered that a protein called Importin-11 protects the anti-cancer protein PTEN from destruction by transporting it into the cell nucleus. A study they publish today in The Journal of Cell Biology suggests that the loss of Importin-11 may destabilize PTEN, leading to the development of lung, prostate, and other cancers.

PTEN prevents tumor cells from growing uncontrollably, and mutations in the gene encoding this are commonly found in many different types of cancer. Some patients, however, show low levels of the PTEN protein even though their PTEN genes are normal. CSHL Associate Professor Lloyd Trotman and colleagues discovered that this may be due to defects in Importin-11, which transports PTEN into the nucleus, sheltering PTEN from proteins in the cell's cytoplasm that would otherwise target it for degradation.

Several cytoplasmic proteins—NEDD4-1, NDFIP1, and UBE2E1—combine to tag PTEN with the small molecule ubiquitin. PTEN tagged with multiple ubiquitin molecules can then be recognized and destroyed by the cell's protein degradation machinery. Trotman and colleagues found that Importin-11 protects PTEN from degradation by escorting not only PTEN but also UBE2E1 into the nucleus, thereby breaking up the cytoplasmic ubiquitination apparatus.

Mice lacking Importin-11 showed lower levels of PTEN protein and developed lung adenocarcinomas and prostate neoplasias. Mutations in the gene encoding Importin-11 have been identified in human cancers, and Trotman and colleagues found that tumors from lacking Importin-11 tended to show low PTEN levels as well. The researchers estimate that loss of Importin-11 may account for the loss of PTEN in approximately one-third of lung cancer patients lacking this key anti-cancer protein.

In prostate cancer, loss of Importin-11 predicted disease relapse and metastasis in patients who had had their prostate removed. "We think that the degradation of PTEN after loss or impairment of Importin-11 is a very effective driver of human ," says Trotman. "Our results suggest that Importin-11 is the 'Achilles' heel' of the ubiquitination system that maintains the correct levels of PTEN inside cells."

Cross sections of prostate tissue in healthy mice (top row) and mice in which cancer is beginning to develop (bottom row). Healthy tissue shows regular structures and empty spaces (white in the far left image) called lumen. Cancerous tissue is less organized, and is more densely populated with cells, which are proliferating abnormally. Insets show consistently that when Ipo11 is abundant, so is PTEN tumor-suppressing protein; when PTEN levels are low, so is the protein Importin 11 (Ipo11). Its presence of absence may be a useful diagnostic and therapeutic marker in prostate biopsies. Credit: Trotman lab, CSHL

Explore further: Researchers identify 'synthetic essentiality' as novel approach for locating cancer therapy targets

More information: "The Nuclear Transport Receptor Importin-11 is a Tumor Suppressor that Maintains PTEN Protein," appears in The Journal of Cell Biology, jcb.rupress.org/cgi/doi/10.1083/jcb.201604025

Related Stories

Researchers identify 'synthetic essentiality' as novel approach for locating cancer therapy targets

February 6, 2017
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential ...

Rare childhood disease linked to major cancer gene

December 1, 2016
A team of researchers led by a University of Rhode Island scientist has discovered an important molecular link between a rare childhood genetic disease, Fanconi anemia, and a major cancer gene called PTEN. The discovery improves ...

New research sheds light on gene destruction linked to aggressive prostate cancer

January 26, 2012
Researchers at Queen's University in Kingston, Canada have identified a possible cause for the loss of a tumour suppressor gene (known as PTEN) that can lead to the development of more aggressive forms of prostate cancer.

COUP-TFII sparks prostate cancer progression

November 28, 2012
Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.